CClinicalTrials.gg
CompletedNCT03302039Updated Dec 17, 2018

Three Protocols for Phenylephrine Administration in Cesarean Delivery

A Phase 4 interventional study of Single shot phenylephrine and Fixed infusion phenylephrine. in Cesarean Section Complications and Spinal Anesthesia, sponsored by Cairo University. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2018-12-17.

Sponsored by Cairo University · Phase 4, Interventional, and Prevention

Phase
Phase 4
Study type
Interventional
Enrollment
217
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The investigators will compare variable infusion of phenylephrine (at a starting rate of 0.75 mcg/Kg/min) with fixed rate (0.75 mcg/Kg/min which will stop of reactive hypertension occurred) and single shot (1.5 mcg/Kg) phenylephrine.

Read the detailed description

Maternal hypotension is a common complication after spinal anesthesia for cesarean delivery (CD). Phenylephrine (PE) is the most popular vasopressor for prevention of post-spinal hypotension (PSH) during CD; however, the most appropriate protocol for PE administration is still unknown. The most common PE protocols used for prophylaxis against PSH are: single shot, fixed infusion, and variable infusion. A recent study reported that a dose of 1.5 mcg/Kg is the most suitable single-shot dose for prophylaxis. Another randomized controlled trial compared four doses of PE infusion and reported that 25 mcg/Kg/min and 50 mcg/Kg/min doses were the best doses for fixed infusion with accepted incidence of both PSH as well as reactive hypertension. Using variable infusion rate of PE had been recently introduced in another study with a starting dose of 0.75 mcg/Kg/min. The variable rate infusion showed very good results regarding PSH. In this study, the investigators will compare variable infusion of PE (at a starting rate of 0.75 mcg/Kg/min) with fixed rate (0.75 mcg/Kg/min which will stop if reactive hypertension occurred) and single shot protocol (1.5 mcg/Kg).

02

Conditions studied

  • Cesarean Section Complications
  • Spinal Anesthesia
03

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Full term
  • Pregnant women
  • Scheduled for cesarean delivery

Exclusion criteria

Exclusion Criteria:

  • Pre-eclampsia
  • Eclampsia
  • Hemorrhage
  • Cardiac dysfunction
  • Baseline low heart rate (below 60 bpm)
04

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
217 participants (actual)

Study arms

  • Experimental
    Single shot

    Spinal anesthesia will be performed using intrathecal bupivacaine. Then, a single shot phenylephrine (1.5 ug/Kg) will be administered.

    Drug: Single shot phenylephrine · Drug: Bupivacaine

  • Active comparator
    Fixed infusion

    Spinal anesthesia will be performed using intrathecal bupivacaine. Then, fixed infusion phenylephrine will be administered at a dose of (0.75 mcg/Kg/min). the infusion will stop if reactive hypertension occurred.

    Drug: Fixed infusion phenylephrine. · Drug: Bupivacaine

  • Active comparator
    Variable infusion

    Spinal anesthesia will be performed using intrathecal bupivacaine. Then, variable infusion phenylephrine will be administered at a starting dose of (0.75 mcg/Kg/min). the infusion will be titrated according to blood pressure.

    Drug: Variable infusion phenylephrine. · Drug: Bupivacaine

Interventions

  • DrugSingle shot phenylephrine

    A single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously.

    Also known as: Phenylephrine

  • DrugFixed infusion phenylephrine.

    Fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min

    Also known as: Phenylephrine

  • DrugVariable infusion phenylephrine.

    Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.

    Also known as: Phenylephrine

  • DrugBupivacaine

    Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia.

    Also known as: Marcaine

05

What researchers measure

Primary outcomes

  1. Incidence of Post-spinal anesthesia hypotension

    Defined as percentage of patients with decreased systolic blood pressure less than 80% of the baseline reading during the period from intrathecal injection to delivery of the fetus

    Time frame: 30 minutes after spinal anesthesia

Secondary outcomes

  1. Incidence of severe Post-spinal anesthesia hypotension

    Defined as percentage of patients with decreased systolic blood pressure less than 60% of the baseline reading during the period from intrathecal injection to delivery of the fetus.

    Time frame: 30 minutes after spinal anesthesia

  2. Incidence of reactive hypertension

    Defined as percentage of patients with increased systolic blood pressure more than 80% of the baseline reading during the period from intrathecal injection to delivery of the fetus.

    Time frame: 2 hours after spinal anesthesia

  3. Systolic blood pressure

    Systolic blood pressure measured in mmHg

    Time frame: 2 hours after spinal anesthesia

  4. Diastolic blood pressure

    Diastolic blood pressure measured in mmHg

    Time frame: 2 hours after spinal anesthesia

  5. Heart rate

    number of heart beats per minute

    Time frame: 2 hours after spinal anesthesia

  6. APGAR score

    APGAR score of the fetus

    Time frame: 10 minutes after delivery

  7. umbilical arterial PH

    the PH in umbilical arterial blood

    Time frame: 10 minutes after delivery

  8. umbilical arterial Pco2

    umbilical arterial Pco2 measured in mmHg

    Time frame: 10 minutes after delivery

06

Study locations

1 site
  • Cairo University
    Cairo, Egypt
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03302039
Lead sponsor
Cairo University
Responsible party
Ahmed Hasanin (Assistant professor, Cairo University) — Principal investigator
First posted
Oct 4, 2017
Start date
Oct 6, 2017
Primary completion
Oct 1, 2018
Completion
Oct 15, 2018
Last update
Dec 17, 2018

Study contacts

Ahmed Mukhtar, Professor
study director · Head of research committee section in anesthesia department

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion